Top cardiology news in 2023: A year of firsts for CVD treatments, procedures, devices
Click Here to Manage Email Alerts
Healio | Cardiology Today compiled a list of some of the most important news in cardiology from 2023.
The most-read articles on Healio in 2023 included news about renal denervation for the treatment of hypertension; results of the SELECT trial of semaglutide for reducing CV risk in adults with CVD and overweight or obesity in the absence of diabetes; FDA approval of the world’s first dual-chamber leadless pacing system; and more. Read these articles, and others, in no particular order, below.
Image: Adobe Stock
Bempedoic acid an ‘effective alternative’ for statin-intolerant patients: CLEAR Outcomes
In the CLEAR Outcomes trial, bempedoic acid (Nexletol, Esperion Therapeutics) reduced risk for major CV events by 13% compared with placebo, including a 23% lower risk for MI, among adults with a history of CVD or at high risk deemed statin intolerant, according to data presented at the ACC Scientific Session. Read more
Semaglutide cuts cardiovascular risk by 20% in people with heart disease, obesity: SELECT
In the SELECT trial, treatment with weekly injectable semaglutide 2.4 mg (Wegovy, Novo Nordisk) was superior to placebo for reducing CV risk in adults with preexisting heart disease and overweight or obesity but without diabetes, according to results presented at the American Heart Association Scientific Sessions. Read more
FDA approves CV version of colchicine for patients with residual inflammatory risk
In June, Agepha Pharma announced that the FDA approved a 0.5 mg dose of colchicine for reduction of CV events in patients with atherosclerotic CVD or multiple CV risk factors who have residual inflammatory risk. Read more
Supreme Court decision allows alirocumab to stay on US market
In May, the U.S. Supreme Court unanimously ruled in favor of Regeneron and Sanofi that two of Amgen’s patents for PCSK9 inhibitor technology were invalid, allowing alirocumab to stay on the U.S. market. Read more
FDA expands dapagliflozin indication to include all patients with HF
In May, the FDA expanded an indication for the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) to reduce risk for CV death, HF hospitalization and urgent HF visits for adults with HF across the full range of ejection fraction. Read more
As real-world renal denervation use begins, an interventionist shares experience, cautions
In November, the FDA approved two renal denervation systems for people with uncontrolled hypertension despite maximally tolerated therapies. The approvals ushered in the first-ever interventional procedures with indications to lower BP. Read more
‘Potential cardiovascular risk’ for some on keto-style diet
Certain traditional risk factors including severe high cholesterol, diabetes, hypertension and smoking may increase CV risk among those following a low-carbohydrate, high-fat “keto-style diet,” according to data presented at the American College of Cardiology Scientific Session. Read more
Oral PCSK9 inhibitor lowers LDL similar to injection in short-term phase 2 trial
In a phase 2 trial, an oral PCSK9 inhibitor (MK-0616, Merck) lowered LDL about the same amount observed with injectable PCSK9 inhibitors for 8 weeks, researchers reported at the ACC Scientific Session. Read more
Number of daily meals, not intermittent fasting, associated with long-term weight change
In the general population, long-term weight change is strongly associated with the average daily number of medium and large meals but not with a specific time-restricted eating strategy, according to a study published in the Journal of the American Heart Association. Read more
New atrial fibrillation guideline highlights early rhythm control, prevention strategies
An updated guideline published in November on the prevention and management of atrial fibrillation includes a new staging system to emphasize disease progression, along with updated recommendations for catheter ablation and left atrial appendage occlusion. Read more
Abelacimab trial for AF stopped early due to ‘overwhelming’ reduction in bleeding
Anthos Therapeutics announced in September that the phase 2 AZALEA-TIMI 71 study was stopped early due to an “overwhelming reduction” in bleeding in patients with atrial fibrillation at high risk for stroke taking abelacimab vs. rivaroxaban. Read more
SGLT2 inhibitor therapy reduces sudden cardiac death risk in heart failure
SGLT2 inhibitor therapy in patients with heart failure is associated with a significantly lower incidence of sudden cardiac death vs. placebo, with the benefit persisting independent of other guideline-directed medical therapies. Read more
‘Game changing’ data: New obesity drugs tied to major weight loss, may reduce CV risk
A new generation of obesity drugs is changing the treatment landscape for patients and providers, with options that can lead to weight loss unheard of just a few years ago. Read more
FDA approves first dual-chamber leadless pacing system
Abbott announced in July that the FDA approved the world’s first dual-chamber leadless pacing system (Aveir DR), which will open up leadless pacemaker technology to a broader population. Read more
Collapse
Healio Coverage
Read more about
Click Here to Manage Email Alerts